观察不同药物治疗难治性心衰的临床价值

目的：对不同药物治疗难治性心襄的疗效进行观察、比较。方法：抽取我院2015年6月～2016年10月期间收治的难治性心襄患者90例，按照随机的方式将所有患者平均分为硝普钠组与新活素组。给予观察组患者硝普钠治疗，对照组患者接受新活素治疗。一周后分别对两组患者的临床疗效、不良反应以及治疗前后超声心动图检查结果进行比较。结果：经过比较，硝普钠组临床总有效率为34／45（75.56％），较低于新活素组43／45（95.56％）（P〈0．05）；虽然两组患者经治疗后临床症状、心功能分级、左室收缩功能及左室舒末径指标均有所改善，但新活素组改善较为显著；且新活素组不良反应发生率11．11％低于硝普钠组17.78％。结论：硝普钠与新活素治疗难治性心表，能够改善难治性心表患者的心脏功能，提高患者生存质量，但新活素组疗效显著，且安全性更高。

Objective ：To observe and compare the therapeutic effects of different drugs in the treatment of refractory heart failure. Methods： a total of 90 patients with refractory heart failure admitted to our hospital from June 2015 to October 2016 were randomly divided into sodium nitroprusside group and new active group. The patients in the observation group were treated with sodium nitroprusside, while the control group received the treatment with Neo biotin.Results： after clinical comparison, sodium nitroprusside group total effective rate was 34/45 （75.56%）, lower Xinhuosu group 43/45 （95.56%） （P〈0.05）; although the two groups of patients after treatment of clinical symptoms, cardiac function,and the Xinhuosu group adverse reaction rate was 11.11% lower than that of sodium nitroprusside group 17.78%.Conclusion：the treatment of refractory heart failure with sodium nitroprusside and new live hormone can improve the cardiac function and improve the quality of life of patients with refractory heart failure.